NCT07367971PHASE1Recruiting

Drug-Drug Interaction Study of ABP-671 in Gout Patients

Atom Therapeutics Co., Ltd

Start Date

1/23/2026

Completion Date

8/31/2026

Summary

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Eligibility Criteria

Age Range: 18 years to 75 years

Inclusion Criteria: * Adults 18-75 years with clinical diagnosis of gout. * Stable Allopurinol therapy QD for ≥14 days prior to Day 1. * Cohort N: Normal renal function. * Cohort R: Moderate renal impairment. Exclusion Criteria: * Clinically significant hepatic impairment. * History of Allopurinol hypersensitivity. * Pregnancy or breastfeeding.

Interventions

DRUG

ABP-671 plus allopurinol

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Gout ChronicGoutDDI (Drug-Drug Interaction)

Locations

Wakefield Clinical Research

Cary, North Carolina 27560

United States